Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers

Targeted therapies are current care standards for various oncogene-driven lung cancers. However, chemotherapy is still an important therapeutic option because resistance to targeted therapy eventually develops. Attempts to improve on the outcomes achieved with chemotherapy alone have led to the development of combination therapies that include a chemotherapy backbone.

Source: Lung Cancer - October 7, 2021 Category: Cancer & Oncology Authors: Martin Gutierrez, Robin Guo, Giuseppe Giaccone, Stephen V. Liu, Zhonglin Hao, Christie Hilton, James M Hinson, Mark G. Kris, Everardus Otto Orlemans, Alexander Drilon Source Type: research